Arcutis Biotherapeutics, Inc. Common Stock
Veridion Score
Composite trend over time
Why is ARQT moving today?
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for ARQT.
ARQT insider activity
Arcutis Biotherapeutics, Inc. Common Stock
No multi-insider buying cluster in the last 90 days
Net selling: -$15.7M across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
| Filing date | Trade date | Insider | Title | Type | Price | Qty | Owned | Value | Receipt |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-13 | 2026-05-11 | Vairavan Latha | Insider | sell | $21.05 | 435 | 85,978 | $9K | SEC Form 4 |
| 2026-05-13 | 2026-05-11 | Burnett Patrick | Insider | sell | $21.05 | 222 | 120,244 | $5K | SEC Form 4 |
| 2026-05-06 | 2026-05-04 | Vairavan Latha | Insider | sell | $23.61 | 1,341 | 86,413 | $32K | SEC Form 4 |
| 2026-05-06 | 2026-05-04 | Watanabe Todd | Insider | sell | $23.61 | 3,172 | 720,755 | $75K | SEC Form 4 |
| 2026-05-06 | 2026-05-04 | Matsuda Masaru | Insider | sell | $23.61 | 884 | 126,689 | $21K | SEC Form 4 |
Showing 5 recent rows. Sovereign unlocks 87 additional rows, full sorting, and the named-filer history.
Upgrade to Sovereign · $25/moARQT contract awards, year to date.
Public federal awards linked to this ticker.
ARQT lobbying filings, year to date.
Registered lobbying filings matched to Arcutis Biotherapeutics, Inc. Common Stock.